v3.26.3
Business Segment
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Business Segment Business Segment
We operate and report our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company derives revenue globally and manages the business on a consolidated basis due to shared infrastructure and resources. Our chief operating decision maker ("CODM"), the President and Chief Executive Officer, evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and allocates resources on a consolidated worldwide basis.
Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine and lower extremities instrumentation and implants, small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and fees related to sales representation, promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic procedures, clinical insufflation, smoke evacuation devices, a line of patient monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Orthopedic surgery$148,834 $138,193 $448,810 $417,216 
General surgery186,723 199,733 547,280 584,310 
Consolidated net sales$335,557 $337,926 $996,090 $1,001,526 
The following table includes significant segment expenses:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net sales
$335,557 $337,926 $996,090 $1,001,526 
Cost of sales(a)
146,409 171,807 426,038 469,336 
Salesforce and commission expense
56,903 59,404 174,268 175,760 
Marketing expense
18,859 16,915 56,151 49,782 
Distribution expense
13,860 13,085 41,283 38,270 
General and administrative expense
30,112 31,941 93,649 97,609 
Stock-based compensation expense
5,911 4,585 16,643 23,352 
Amortization expense
7,247 7,233 21,745 21,597 
Non-cash adjustments to fair value of contingent consideration liability605 1,341 1,215 3,504 
Research and development expense(b)
15,588 13,901 47,421 40,985 
Interest expense
11,135 7,606 26,078 23,716 
Other (income)/expense— — (2,825)418 
Provision for income taxes
6,213 1,414 19,016 11,548 
Other segment items(c)
2,919 5,835 18,713 15,333 
Net income
$19,796 $2,859 $56,695 $30,316 
(a)Cost of sales in 2026 includes a charge for inventory, equipment, and tooling related to the discontinuation of certain products for the nine months ended September 30, 2026 and a net benefit for the early termination of our distribution agreement with W.L. Gore & Associates, Inc for the nine months ended September 30, 2026. Cost of sales in 2025 includes the write off of inventory, equipment, tooling and patents related to the cancellation of planned new product lines and discontinuation of certain catalog numbers as a result of our operational optimization consultation and internal review for the three and nine months ended September 30, 2025. In addition, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales for the three and nine months ended September 30, 2025.

(b)Research and development expense includes costs to comply with the European Union's Medical Device Regulations in the three and nine months ended September 30, 2026.

(c)Other segment items consist of (i) consulting fees, legal fees, and other costs related to operational optimization in the three and nine months ended September 30, 2026 and 2025; (ii) cash compensation costs related to advisory services provided by our former Chief Financial Officer and Chief Executive
Officer in the nine months ended September 30, 2026 and 2025, respectively; (iii) loss from the sale of additional assets related to the gastroenterology product offerings which was recorded as a sale of a business in the nine months ended September 30, 2026; (iv) a gain from the sale of certain assets related to gastroenterology products in the three and nine months ended September 30, 2026; (v) third party services pertaining to the review of potential issues with certain royalty payments to surgeons involved in design teams in three and nine months ended September 30, 2025; and (vi) gain on the sale of a product offering in the nine months ended September 30, 2025.
Total assets for the Company's single operating segment are the same as presented on the Company's consolidated balance sheet, which is used to measure segment performance.